Physician profile
Rachel E Bargo
NPI 1396145447
$1,284.34
in general payments reported to CMS, 2019-2025
14 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $244 · 2023: $365 · 2024: $198 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $305.14 | 2022-2025 | |
| Abbvie INC. | $142.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $131.13 | 2021-2025 | Farxiga |
| Amgen INC. | $77.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $74.17 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $73.45 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $41.89 | 2021 | |
| Dexcom, INC. | $34.90 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $25.48 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $17.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2021 | |
| Hologic Sales and Service, LLC | $16.25 | 2023 | Aptima |
| Novartis Pharmaceuticals Corporation | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.